CEO / Co-Founder
AN2 Therapeutics
AN2 Therapeutics develops boron-based compounds aimed at creating first-in-class therapeutics for infectious diseases and oncology. Their approach addresses the need for novel treatment options in these critical areas of global health.
- Biotechnology
Updated 23 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Infectious diseases and oncology often lack effective treatment options due to the limitations of traditional carbon-based molecules in addressing certain biological targets. Current therapies for diseases like Chagas disease, melioidosis, and non-tuberculous mycobacterial (NTM) lung disease can have inconsistent efficacy and significant side effects, leaving a critical need for novel therapeutics.
Solution
AN2 Therapeutics is developing boron-based small molecule therapeutics to combat infectious diseases and cancers. Their boron chemistry platform enables the creation of first-in-class drugs that can bind to biological targets previously considered undruggable by traditional methods. By tuning the properties of boron-based inhibitors, AN2 Therapeutics can optimize drug characteristics such as selectivity, solubility, and metabolic stability. Their pipeline includes compounds targeting chronic _Trypanosoma cruzi_ infection (Chagas disease) and _Burkholderia pseudomallei_ (melioidosis), as well as treatments for _Mycobacterium abscessus_ lung disease.
Target Audience
The primary target audience includes patients suffering from infectious diseases such as Chagas disease, melioidosis, and NTM lung disease, as well as healthcare providers seeking novel therapeutic options.
Features
- Boron chemistry platform enabling reversible covalent bonds with biological targets
- Ability to "tune" boron's reactive center to modulate drug properties
- Highly selective inhibitors minimizing off-target effects
- AN2-502998: Oral therapeutic candidate for chronic Chagas disease, demonstrating curative activity in preclinical studies
- Epetraborole: Inhibitor of bacterial leucyl-tRNA synthetase (LeuRS) for the treatment of melioidosis and NTM lung disease
- Potential to improve efficacy of existing treatments when used in combination therapies